These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 35273002)

  • 21. Comparative study of prophylaxis with high and low doses of voriconazole in children with malignancy.
    L Kandaurava S; S Baslyk K; A Migas A; V Hill A; I Bydanov O; A Mishkova V; V Aleinikova O
    Curr Med Mycol; 2020 Dec; 6(4):27-34. PubMed ID: 34195457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and Adsorptive Analyses of Administration of Oral Voriconazole Suspension via Enteral Feeding Tube in Intensive Care Unit Patients.
    Tanaka R; Eto D; Goto K; Ohchi Y; Yasuda N; Suzuki Y; Tatsuta R; Kitano T; Itoh H
    Biol Pharm Bull; 2021; 44(5):737-741. PubMed ID: 33952830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Genetic Polymorphism of CYP3A5 and CYP2C19 and Concomitant Use of Voriconazole on Blood Tacrolimus Concentration in Patients Receiving Hematopoietic Stem Cell Transplantation.
    Iwamoto T; Monma F; Fujieda A; Nakatani K; Gayle AA; Nobori T; Katayama N; Okuda M
    Ther Drug Monit; 2015 Oct; 37(5):581-8. PubMed ID: 25565672
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tacrolimus Concentration after Letermovir Initiation in Hematopoietic Stem Cell Transplantation Recipients Receiving Voriconazole: A Retrospective, Observational Study.
    Hikasa S; Shimabukuro S; Osugi Y; Ikegame K; Kaida K; Fukunaga K; Higami T; Tada M; Tanaka K; Yanai M; Kimura T
    Int J Med Sci; 2020; 17(7):859-864. PubMed ID: 32308538
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retrospective serological tests for determining the optimal blood concentration of voriconazole for treating fungal infection.
    Okuda T; Okuda A; Watanabe N; Takao M; Takayanagi K
    Yakugaku Zasshi; 2008 Dec; 128(12):1811-8. PubMed ID: 19043301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential effects of C-reactive protein levels on voriconazole metabolism at three age groups in allogeneic hematopoietic cell transplant recipients.
    Luo X; Li T; Hu L; Liu S; Zhao H; Zhang J; Feng Y; Huang L
    J Chemother; 2021 Apr; 33(2):95-105. PubMed ID: 32441568
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Visual disturbance or central symptom like hallucination in patients treated voriconazole: report of six cases.
    Kato H; Hagihara M; Hamada Y; Koizumi Y; Nishiyama N; Yamagishi Y; Matsuura K; Mikamo H
    Jpn J Antibiot; 2016 Sep; 69(3):143-150. PubMed ID: 30226950
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis.
    Hamada Y; Seto Y; Yago K; Kuroyama M
    J Infect Chemother; 2012 Aug; 18(4):501-7. PubMed ID: 22231601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of oral voriconazole during chemotherapy for acute myeloid leukemia and myelodysplastic syndrome: a Japanese nationwide retrospective cohort study.
    Tsutsumi I; Kunisawa S; Yoshida C; Seki M; Komeno T; Fushimi K; Morita S; Imanaka Y
    Int J Clin Oncol; 2019 Nov; 24(11):1449-1458. PubMed ID: 31300904
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selection of Oral Antifungals for Initial Maintenance Therapy in Chronic Pulmonary Aspergillosis: A Longitudinal Analysis.
    Tashiro M; Takazono T; Saijo T; Yamamoto K; Imamura Y; Miyazaki T; Kakeya H; Ando T; Ogawa K; Kishi K; Tokimatsu I; Hayashi Y; Fujiuchi S; Yanagihara K; Miyazaki Y; Ichihara K; Mukae H; Kohno S; Izumikawa K
    Clin Infect Dis; 2020 Feb; 70(5):835-842. PubMed ID: 30959519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of switching from intravenous to oral administration on serum voriconazole concentration.
    Harada S; Niwa T; Hoshino Y; Fujibayashi A; Suzuki A
    J Clin Pharm Ther; 2021 Jun; 46(3):780-785. PubMed ID: 33393135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of
    Ebrahimpour S; Namazi S; Mohammadi M; Nikbakht M; Hadjibabaie M; Masoumi HT; Ghavamzadeh A
    J Res Pharm Pract; 2017; 6(3):151-157. PubMed ID: 29026840
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Voriconazole-medicalneeds, evidence, potential for the future].
    Shirasawa H; Nagino K
    Nihon Ishinkin Gakkai Zasshi; 2005; 46(4):223-8. PubMed ID: 16282963
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Population pharmacokinetics, safety and dosing optimization of voriconazole in patients with liver dysfunction: A prospective observational study.
    Tang D; Yan M; Song BL; Zhao YC; Xiao YW; Wang F; Liang W; Zhang BK; Chen XJ; Zou JJ; Tian Y; Wang WL; Jiang YF; Gong GZ; Zhang M; Xiang DX
    Br J Clin Pharmacol; 2021 Apr; 87(4):1890-1902. PubMed ID: 33010043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of voriconazole and its alteration by Candida albicans infection in silkworms.
    Yasu T; Matsumoto Y; Sugita T
    J Antibiot (Tokyo); 2021 Jul; 74(7):443-449. PubMed ID: 34045695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Case of Scedosporium apiospermum cutaneous soft tissue infection treated with voriconazole].
    Konishi M; Yonekawa S; Nakagawa C; Uno K; Kasahara K; Yoshimoto E; Maeda K; Mikasa K
    Kansenshogaku Zasshi; 2008 Mar; 82(2):82-5. PubMed ID: 18411765
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infantile Aspergillus fumigatus ventriculitis successfully treated with monitoring of plasma and cerebrospinal fluid voriconazole concentration level.
    Furudate A; Hirose S; Abe K; Kawashima A; Hashimoto K; Yamazaki S; Kamei K; Ishiwada N; Hamada H; Sato M
    J Infect Chemother; 2020 Jan; 26(1):132-135. PubMed ID: 31350185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and safety of the simulation-based first-dose design of voriconazole.
    Umemura T; Kakizaki H; Mutoh Y; Mizuno T; Ito Y; Hioki T; Kato H; Hagihara M; Yamada T; Ikeda Y; Mikamo H; Ichihara T; Hamada Y
    J Infect Chemother; 2024 Jun; ():. PubMed ID: 38944383
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bioavailability of voriconazole in hospitalised patients.
    Veringa A; Geling S; Span LF; Vermeulen KM; Zijlstra JG; van der Werf TS; Kosterink JG; Alffenaar JC
    Int J Antimicrob Agents; 2017 Feb; 49(2):243-246. PubMed ID: 28012684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic drug monitoring of voriconazole and CYP2C19 phenotype for dose optimization in paediatric patients.
    Hu L; Huang Q; Huang S; Feng Z
    Eur J Clin Pharmacol; 2023 Sep; 79(9):1271-1278. PubMed ID: 37458772
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.